Lifecore Biomedical, Inc. De annual free cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2025
Lifecore Biomedical, Inc. De Free Cash Flow (FCF) History (LFCR)
Lifecore Biomedical, Inc. De reported $3.6M in free cash flow for fiscal 2025, a free cash flow margin of 4.81%.
View full Lifecore Biomedical, Inc. De company overviewLifecore Biomedical, Inc. De free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 · Dec 31 | 2025-12-31 | $3.6M | — | — | +4.81% |
| 2025 · May 25 | 2025-05-25 | −$13.6M | $4.5M | — | −10.57% |
| 2024 | 2024-05-26 | −$18.1M | $20.8M | — | −14.14% |
| 2023 | 2023-05-28 | −$38.9M | $9.9M | — | −37.69% |
| 2022 | 2022-05-29 | −$48.8M | −$46.0M | — | −43.87% |
| 2021 | 2021-05-30 | −$2.8M | $26.5M | — | −2.77% |
| 2020 | 2020-05-31 | −$29.3M | −$541,000 | — | −18.28% |
| 2019 | 2019-05-26 | −$28.7M | −$14.9M | — | −5.15% |
| 2018 | 2018-05-27 | −$13.8M | −$20.6M | — | −2.63% |
| 2017 | 2017-05-28 | $6.8M | $25.8M | — | +1.45% |
| 2016 | 2016-05-29 | −$18.9M | −$28.0M | — | −3.97% |
| 2015 | 2015-05-31 | $9.1M | $2.9M | +47.86% | +1.69% |
| 2014 | 2014-05-25 | $6.2M | −$6.2M | −50.14% | +1.29% |
| 2013 | 2013-05-28 | $12.4M | −$4.5M | −26.51% | +2.80% |
| 2012 | 2012-05-27 | $16.8M | $9.0M | +115.93% | +5.29% |
| 2011 | 2011-05-29 | $7.8M | $5.5M | +239.81% | +2.81% |
| 2010 | 2010-05-30 | $2.3M | — | — | +0.96% |
Lifecore Biomedical, Inc. De quarterly free cash flow
Q1.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$2.7M | — | — | −7.91% |
| Q1 2026 | 2026-03-31 | $3.6M | — | — | +15.44% |
| Q4 2025 | 2025-12-31 | −$6.6M | — | — | — |
| Q3 2025 · Sep 30 | 2025-09-30 | $25,000 | — | — | +0.08% |
| Q4 2025 | 2025-05-25 | $3.3M | −$2.8M | −45.83% | +8.92% |
| Q3 2025 · Feb 23 | 2025-02-23 | −$4.3M | $3.5M | — | −12.11% |
| Q2 2025 | 2024-11-24 | −$8.6M | −$5.6M | — | −26.35% |
| Q1 2025 | 2024-08-25 | −$4.0M | $9.3M | — | −16.33% |
| Q4 2024 | 2024-05-26 | $6.0M | — | — | +15.85% |
| Q3 2024 | 2024-02-25 | −$7.8M | $11.0M | — | −21.80% |
| Q2 2024 | 2023-11-26 | −$3.0M | $3.2M | — | −9.86% |
| Q1 2024 | 2023-08-27 | −$13.4M | −$8.9M | — | −54.58% |
| Q3 2023 | 2023-02-26 | −$18.8M | $4.4M | — | −70.94% |
| Q2 2023 | 2022-11-27 | −$6.2M | $4.6M | — | −28.36% |
| Q1 2023 | 2022-08-28 | −$4.5M | $2.1M | — | −18.81% |
| Q4 2022 | 2022-05-29 | −$8.2M | −$6.2M | — | −29.30% |
| Q3 2022 | 2022-02-27 | −$23.3M | −$11.4M | — | −66.04% |
| Q2 2022 | 2021-11-28 | −$10.8M | −$9.2M | — | −42.12% |
| Q1 2022 | 2021-08-29 | −$6.5M | −$19.1M | — | −29.26% |
| Q4 2021 | 2021-05-30 | −$2.0M | $20.6M | — | −4.48% |
| Q3 2021 | 2021-02-28 | −$11.8M | −$16.3M | — | −42.55% |
| Q2 2021 | 2020-11-29 | −$1.6M | $14.0M | — | −6.53% |
| Q1 2021 | 2020-08-30 | $12.6M | $28.0M | — | +55.58% |
| Q4 2020 | 2020-05-31 | −$22.6M | −$9.6M | — | −14.48% |
| Q3 2020 | 2020-02-23 | $4.5M | $6.4M | — | +2.94% |
| Q2 2020 | 2019-11-24 | −$15.5M | −$14.0M | — | −10.89% |
| Q1 2020 | 2019-08-25 | −$15.4M | −$3.2M | — | −11.12% |
| Q4 2019 | 2019-05-26 | −$13.0M | $10.1M | — | −8.52% |
| Q3 2019 | 2019-02-24 | −$1.9M | −$10.9M | — | −1.23% |
| Q2 2019 | 2018-11-25 | −$1.5M | −$4.2M | — | −1.23% |
| Q1 2019 | 2018-08-26 | −$12.3M | −$10.0M | — | −9.83% |
| Q4 2018 | 2018-05-27 | −$23.2M | $6.8M | — | −16.42% |
| Q3 2018 | 2018-02-25 | $9.0M | −$12.9M | −58.85% | +6.21% |
| Q2 2018 | 2017-11-26 | $2.6M | −$4.5M | −63.04% | +2.14% |
| Q1 2018 | 2017-08-27 | −$2.3M | −$10.1M | — | −1.97% |
| Q4 2017 | 2017-05-28 | −$30.0M | −$30.8M | — | −24.73% |
| Q3 2017 | 2017-02-26 | $21.9M | $28.7M | — | +16.92% |
| Q2 2017 | 2016-11-27 | $7.1M | $14.8M | — | +6.45% |
| Q1 2017 | 2016-08-28 | $7.8M | $13.1M | — | +7.19% |
| Q4 2016 | 2016-05-29 | $796,000 | −$5.1M | −86.58% | +0.59% |
| Q3 2016 | 2016-02-28 | −$6.8M | −$13.8M | — | −5.24% |
| Q2 2016 | 2015-11-29 | −$7.7M | −$4.0M | — | −5.46% |
| Q1 2016 | 2015-08-30 | −$5.3M | −$5.1M | — | −3.88% |
| Q4 2015 | 2015-05-31 | $5.9M | $3.4M | +135.72% | +4.41% |
| Q3 2015 | 2015-03-01 | $7.0M | −$71,000 | −1.01% | +5.02% |
| Q2 2015 | 2014-11-30 | −$3.6M | −$49,000 | — | −2.74% |
| Q1 2015 | 2014-08-31 | −$155,000 | −$348,000 | — | −0.12% |
| Q4 2014 | 2014-05-25 | $2.5M | — | — | +2.08% |
| Q3 2014 | 2014-02-23 | $7.0M | −$2.8M | −28.51% | +5.56% |
| Q2 2014 | 2013-11-24 | −$3.6M | $371,000 | — | −2.98% |
| Q1 2014 | 2013-08-25 | $193,000 | −$2.9M | −93.68% | +0.18% |
| Q3 2013 | 2013-02-24 | $9.8M | $1.4M | +16.68% | +8.34% |
| Q2 2013 | 2012-11-25 | −$4.0M | $2.6M | — | −3.45% |
| Q1 2013 · Aug 26 | 2012-08-26 | $3.1M | $259,000 | +9.26% | +2.99% |
| Q4 2012 | 2012-05-27 | $12.2M | — | — | +14.73% |
| Q3 2012 | 2012-02-26 | $8.4M | — | — | +10.53% |
| Q2 2012 | 2011-11-27 | −$6.6M | — | — | −8.07% |
| Q1 2012 | 2011-08-28 | $2.8M | $90,000 | +3.32% | +3.82% |
| Q1 2011 | 2010-08-29 | $2.7M | — | — | +4.17% |
Lifecore Biomedical, Inc. De free cash flow growth trends
Lifecore Biomedical, Inc. De's latest reported quarter, Q2 2026, generated −$2.7M in free cash flow.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Lifecore Biomedical, Inc. De source filings ↗Community posts
Webster agrees Lifecore buyout with cash and contingent payments
Lifecore Biomedical ($LFCR) has agreed to be acquired by a Webster Equity Partners affiliate. Common shareholders would receive $6.28 in cash per share at closing, a 49.5% premium to the preceding trading day’s close, plus a non-tradable co ...
